These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36439491)

  • 1. Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
    Nakatsumi H; Komatsu Y; Muranaka T; Yuki S; Kawamoto Y; Harada K; Dazai M; Tateyama M; Sasaki Y; Miyagishima T; Tsuji Y; Katagiri M; Nakamura M; Sogabe S; Hatanaka K; Meguro T; Kobayashi T; Ishiguro A; Muto O; Shindo Y; Kotaka M; Ando T; Takagi R; Sakamoto N; Sakata Y
    Front Oncol; 2022; 12():939425. PubMed ID: 36439491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
    Nakatsumi H; Komatsu Y; Harada K; Kawamoto Y; Yuki S; Sawada K; Ishiguro A; Sogabe S; Ando T; Sasaki Y; Yoshikawa A; Nakamura M; Dazai M; Tateyama M; Muto O; Kotaka M; Sagawa T; Muranaka T; Hatanaka K; Takagi R; Sakata Y
    Int J Cancer; 2024 Dec; 155(12):2223-2231. PubMed ID: 39143041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
    Yasui H; Okita Y; Nakamura M; Sagawa T; Watanabe T; Kataoka K; Manaka D; Shiraishi K; Akazawa N; Okuno T; Shimura T; Shiozawa M; Sunakawa Y; Ota H; Kotaka M; Okuyama H; Takeuchi M; Ichikawa W; Fujii M; Tsuji A
    ESMO Open; 2023 Oct; 8(5):101636. PubMed ID: 37703596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
    Lorenzen S; Schwarz A; Pauligk C; Goekkurt E; Stocker G; Knorrenschild JR; Illerhaus G; Dechow T; Moehler M; Moulin JC; Pink D; Stahl M; Schaaf M; Goetze TO; Al-Batran SE
    BMC Cancer; 2023 Jun; 23(1):561. PubMed ID: 37337155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
    Ottaiano A; Scala S; Santorsola M; Trotta AM; D'Alterio C; Portella L; Clemente O; Nappi A; Zanaletti N; De Stefano A; Avallone A; Granata V; Notariello C; Luce A; Lombardi A; Picone C; Petrillo A; Perri F; Tatangelo F; Di Mauro A; Albino V; Izzo F; Rega D; Pace U; Di Marzo M; Chiodini P; De Feo G; Del Prete P; Botti G; Delrio P; Caraglia M; Nasti G
    Ther Adv Med Oncol; 2021; 13():1758835921989223. PubMed ID: 33854566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
    Matsumoto T; Yamamoto Y; Kotaka M; Masuishi T; Tsuji Y; Shoji H; Hirata K; Tsuduki T; Makiyama A; Izawa N; Takahashi N; Tsuda M; Yasui H; Ohta T; Kito Y; Otsu S; Hironaka S; Yamazaki K; Boku N; Hyodo I; Yoshimura K; Muro K
    Target Oncol; 2024 Mar; 19(2):181-190. PubMed ID: 38427280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
    Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
    Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
    Yamada Y; Matsuhashi N; Fujii H; Makiyama A; Iihara H; Takahashi T; Watanabe D; Kiyama S; Kobayashi R; Suzuki A; Yoshida K
    Anticancer Res; 2021 Jan; 41(1):533-541. PubMed ID: 33419853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
    Jo H; Lee MS; Lee YP; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):e323-e328. PubMed ID: 35248464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
    Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
    Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).
    El-Deiry WS; Winer A; Slifker M; Taylor S; Adamson BJS; Meropol NJ; Ross EA
    Front Oncol; 2019; 9():142. PubMed ID: 30923702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.